Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the revenue story tells you if you are weighing up treatment in the UK
Why Wegovy's 2024 revenue figures matter beyond the headline
Record pharmaceutical sales figures rarely feel relevant to someone sitting at home wondering whether to try a weight-loss medicine. But Wegovy's 2024 revenue trajectory is worth understanding, because it shaped what was actually available on UK shelves and what comes next.
For most of 2023 and into 2024, UK patients found Wegovy harder to access than its sales suggested. Global demand, concentrated in the US, consumed Novo Nordisk's manufacturing capacity. UK supply was formally listed as constrained by the MHRA for extended periods, and many clinics found certain doses unavailable. The revenue surge reflected US prescribing volumes, not UK availability. That distinction matters if you are researching what you can realistically obtain.
By the second half of 2024 the picture shifted. Novo Nordisk expanded manufacturing, and UK supply of the standard dose range became more consistent. That improvement fed directly into 2024's global numbers. The subsequent MHRA approval of the 7.2mg maintenance dose in January 2026 (followed by the dedicated single-dose 7.2mg pen in April 2026) signals that the UK is now a sustained, growing part of Novo Nordisk's commercial focus, not an afterthought. You can read the formal approval announcement via the GOV.UK news release on the 7.2mg pen.
The broader picture of semaglutide's revenue growth across both its weight-loss and diabetes products gives useful context for anyone tracking how the market is developing.
Does record revenue mean the medicine is proven, or just popular?
A fair question. High sales can reflect marketing as much as medicine. In Wegovy's case the clinical evidence came first. The STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, in adults with obesity or overweight plus a weight-related condition, alongside lifestyle changes. NICE formally recommended semaglutide for weight management in the UK (TA875, published March 2023), and the NHS has been rolling out access through specialist weight management services since then.
The revenue reflects that evidence base landing in clinical practice at scale. It also reflects something else: demand from people who cannot access treatment through the NHS, either because they do not meet the current thresholds or because waiting lists are long. Wegovy's licensed indications have also expanded (it now holds UK authorisations covering cardiovascular risk reduction and, as of July 2026, a form of fatty liver disease) which adds to its commercial story beyond weight management alone.
Popularity and evidence are not the same thing, but in this case both point in the same direction. The NICE technology appraisal for semaglutide (TA875) is the clearest summary of what the UK regulatory and clinical establishment concluded.
What 2024's supply and revenue data means for private access today
If you are exploring private treatment, the 2024 revenue story has a practical implication: supply is in a different place now than it was eighteen months ago. The shortages that dominated 2023 and early 2024 are largely resolved for the standard dose range, and the market has matured.
That maturity has not made treatment cheap. Private Wegovy pricing in the UK reflects the cost of a genuine, regulated supply chain, a clinical consultation, and the ongoing prescriber oversight that a prescription-only medicine requires. Understanding how semaglutide sales in 2024 broke down by region helps explain why UK private prices sit where they do, UK volumes were lower than US volumes for most of the year, so economies of scale arrived later here.
One thing worth knowing practically: Wegovy pens are stored in the fridge, ideally somewhere consistent like a dedicated shelf in the door rather than next to anything that might freeze. Keeping that routine steady matters for the medicine's stability; the exact room-temperature window for travel is set out in the Patient Information Leaflet rather than approximated here.
For a fuller picture of the medicine itself, the semaglutide overview covers mechanism, eligibility, and what treatment involves. If you are also thinking about practical side effects that come up with longer-term use (such as maintaining muscle mass on Wegovy) those are worth reading before you start rather than after.
The decision frame: what this revenue context should and should not change
Revenue figures are useful background. They tell you the medicine is manufactured at scale by a company with significant regulatory oversight, that the evidence base is substantial enough to drive institutional adoption, and that UK supply has stabilised. None of that replaces a clinical assessment.
Semaglutide is a prescription-only medicine. The prescriber reviewing your consultation considers your BMI, your health history, any medicines you already take, and whether the treatment is appropriate for you specifically. A large global sales number does not change that requirement, and it should not make the decision feel automatic.
It is also worth separating the manufacturer's commercial story from where you obtain treatment. The question of how to access Wegovy through a regulated UK pharmacy is distinct from what Novo Nordisk reported to its shareholders. What matters for your safety is whether the pharmacy dispensing to you holds a GPhC registration and operates within the licensed UK supply chain, verifiable at the GPhC pharmacy register.
If you have read enough background and want a prescriber to assess whether Wegovy suits your situation, you can start your free consultation with our clinical team.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.